Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.68 |
| ▸ | APP | P05067 | 9/20 | 0.68 |
| ▸ | BCHE | P06276 | 8/20 | 0.68 |
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | MERTK | Q12866 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | GRK6 | P43250 | 1/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23747974 | 0.93 | ACHE (0.71) | ACHEAPPBCHECASP6RAD52 | |
| SCHEMBL30125346 | 0.89 | TRIM58 (0.67) | ACHEAPPBCHECASP6RAD52 | |
| SCHEMBL23723490 | 0.89 | TRIM58 (0.67) | ACHEAPPBCHECASP6RAD52 | |
| SCHEMBL23748931 | 0.88 | ACHE (0.61) | ACHEAPPBCHECASP6RAD52 | |
| SCHEMBL23747984 | 0.84 | APP (0.76) | ACHEAPPBCHERAD52SLC2A1 | |
| SCHEMBL30125352 | 0.84 | ACHE (0.68) | ACHEAPPBCHECASP6RAD52 | |
| SCHEMBL23723423 | 0.84 | ACHE (0.68) | ACHEAPPBCHECASP6RAD52 | |
| SCHEMBL8547756 | 0.81 | APP (0.76) | ACHEAPPBCHECASP6SLC2A1 | |
| SCHEMBL23747983 | 0.81 | ACHE (0.64) | ACHEAPPBCHERAD52AURKA | |
| SCHEMBL23748989 | 0.81 | LMNA (0.61) | ACHEAPPBCHECASP6RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| EP-4100395-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | Trobio Therapeutics Pty Ltd (AU) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021155426-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | NQO2, TP53, ABL1 | ACHE 1215/4885APP 4864/4885BCHE 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.